Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D E Furst

Showing results (191-200 of 251) with videos related to

Pageof 26
Sort By:
The Journal of Rheumatology|April 1, 1987
A strategy for reaching therapeutic salicylate levels in patients with rheumatoid arthritis using standardized dosing regimensD E Furst, K Blocka, S Cassell, et al.
Annals of the Rheumatic Diseases|March 14, 2002
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001)D E Furst, E C Keystone, F C Breedveld, et al.
Arthritis and Rheumatism|April 9, 2005
Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy studyJ S Smolen, C Han, M Bala, et al.
Journal of Clinical Pharmacology|February 1, 1994
Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug developmentC C Peck, W H Barr, L Z Benet, et al.
Rheumatology (Oxford, England)|August 22, 2006
Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosisO Distler, F Behrens, D Huscher, et al.
Clinical Pharmacology and Therapeutics|April 1, 1992
Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug developmentC C Peck, W H Barr, L Z Benet, et al.
Journal of Pharmaceutical Sciences|June 1, 1992
Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug developmentC C Peck, W H Barr, L Z Benet, et al.
Rheumatology (Oxford, England)|December 2, 2004
HLA allelic variants encoding DR11 in diffuse and limited systemic sclerosis in Caucasian womenL S Loubière, N C Lambert, M M Madeleine, et al.
The Journal of Rheumatology|February 11, 1998
The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosisD E Furst, P J Clements, V D Steen, et al.
Pharmaceutical Research|June 1, 1992
Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug developmentC C Peck, W H Barr, L Z Benet, et al.
Pageof 26

Showing results (191-200 of 251) with videos related to

Sort By:
Pageof 26
The Journal of Rheumatology|April 1, 1987
A strategy for reaching therapeutic salicylate levels in patients with rheumatoid arthritis using standardized dosing regimensD E Furst, K Blocka, S Cassell, et al.
Annals of the Rheumatic Diseases|March 14, 2002
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001)D E Furst, E C Keystone, F C Breedveld, et al.
Arthritis and Rheumatism|April 9, 2005
Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy studyJ S Smolen, C Han, M Bala, et al.
Journal of Clinical Pharmacology|February 1, 1994
Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug developmentC C Peck, W H Barr, L Z Benet, et al.
Rheumatology (Oxford, England)|August 22, 2006
Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosisO Distler, F Behrens, D Huscher, et al.
Clinical Pharmacology and Therapeutics|April 1, 1992
Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug developmentC C Peck, W H Barr, L Z Benet, et al.
Journal of Pharmaceutical Sciences|June 1, 1992
Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug developmentC C Peck, W H Barr, L Z Benet, et al.
Rheumatology (Oxford, England)|December 2, 2004
HLA allelic variants encoding DR11 in diffuse and limited systemic sclerosis in Caucasian womenL S Loubière, N C Lambert, M M Madeleine, et al.
The Journal of Rheumatology|February 11, 1998
The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosisD E Furst, P J Clements, V D Steen, et al.
Pharmaceutical Research|June 1, 1992
Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug developmentC C Peck, W H Barr, L Z Benet, et al.
Pageof 26